Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

101.74 +1.05 (+1.04%)
Streaming Delayed Price Updated: 2:06 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Merck & Co. Inc. (NYSE:MRK) Stands Out as a Durable Dividend Stock ↗
Merck (MRK) offers a strong 3.43% dividend yield, backed by a history of increases, high profitability, and solid financial health for durable income. 
Via Chartmill
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Merck Scores FDA Fast-Track Review For Key Cholesterol And Cancer Drugs With Multibillion-Dollar Potential: Report ↗
While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide decanoate, the other is its cancer therapy Sacituzumab tirumotecan. 
Via Stocktwits
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast ↗
Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall... 
Via MarketMinute
Topics Intellectual Property
News headline image
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗
Each company has a bullish case, but three stand out as great long-term buys. 
Via The Motley Fool
Topics Bonds Economy Intellectual Property
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
7 Dividend ETFs to Buy With $2,000 and Hold Forever -- Including the Schwab U.S. Dividend Equity ETF (SCHD) ↗
It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly. 
Via The Motley Fool
Topics ETFs
News headline image
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026 ↗
They could grow into their valuation over the next few years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Green Revolution in Silicon: Semiconductor Manufacturing Embraces Sustainability
The semiconductor industry, the foundational bedrock of our digital world and the engine powering the explosive growth of artificial intelligence, is undergoing a profound transformation. Driven by... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Economy
News headline image
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing... 
Via StockStory
News headline image
Dividend Stocks for 2026: Where to Invest as the Market Cools ↗
Via MarketBeat
News headline image
2 Pharmaceutical Stocks to Buy at a Discount ↗
Investors are currently so focused on one type of drug that even good companies are being left on the sidelines. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare Sector Falters: S&P 500's Biggest Loser Amid Broader Market Caution
New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump ↗
The company is finding ways to overcome the headwinds it will encounter in the medium term. 
Via The Motley Fool
News headline image
1 Major Factor Behind the Healthcare Sector's Recent Surge ↗
Blockbuster drugs are a major driver of the growth of healthcare stocks. 
Via The Motley Fool
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? ↗
After a long hiatus, why are the bulls so willing to buy in now? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here. 
Via The Motley Fool
News headline image
Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗
The rebound is well underway. 
Via The Motley Fool
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.